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 Introduction: 
                                 
End stage renal disease (ESRD) represents a clinical state or condition in which there has been 
an irreversible loss of endogenous renal function, of a degree sufficient to render the patient 
permanently dependent upon renal replacement therapy in order to avoid life-threatening 
uraemia. Patients with ESRD have decreased quality of life, high morbidity and an annual 
mortality of about 22%. Renal replacement therapy (RRT) is required when kidney function 
deteriorates to the point where the accumulation of the waste products begins to interfere with 
life function. 
          Peritoneal dialysis, haemodialysis and renal transplantation are the major 
modalities of renal replacement therapy. The number of the patients kept alive by dialysis 
therapy continues to increase each year. The morbidity and mortality in the patients under going 
dialysis is a rapidly emerging problem. Dialysis is a procedure, which serves as a bridge to renal 
transplantation.  . There are many studies going on to analyze the merits and demerits of the 
dialysis procedure. 
 
  
 
 
             We did this study to analyze one of the demerits of the peritoneal dialysis, 
hyperlipidaemias in the patients under going the peritoneal dialysis. 
                   In our hospital we have a large number of chronic renal failure patients, who 
fulfilled the criteria for undergoing the dialysis; this study was conducted in such patients with 
their full co-operation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of the study 
 
1. To estimate the various level of lipid abnormalities in the chronic kidney disease patients 
under going peritoneal dialysis. 
2. To estimate which lipid abnormalities is more common in the study group. 
3. To study, if correlation exists between the peritoneal dialysis and the levels of the 
atherogenic lipids. 
4.  To estimate, whether the abnormal lipids induced by peritoneal dialysis shows any 
correlation with the cardiovascular disease.  
     
 
  
 
 
 
 
 
 
 
Inclusion criteria for the case selection:       
1. Elevated renal parameters, with urea: creatinine ratio <20. 
 
2. Reduced creatinine clearance < 30ml/min. 
 
3. Contracted kidneys as evidenced by the ultrasound scan abdomen. Kidney Size of < 9.0 
x4.0 cms. 
 4. History of treatment for Systemic hypertension for the minimum of two yrs duration, but 
not on chronic β blocker therapy. 
 
5. Patient’s general conditions to withstand the dialysis procedure for a continuous period 
of 48 hrs. 
 
6. Age > 40yrs. 
 
 
 
 
 
Exclusion criteria for the case selection:  
 
1. Patients with known history of Diabetes Mellitus and who were not known diabetics 
with elevated random blood sugar   values of  >200mgs % was excluded  
2. A known ischaemic heart disease patient on treatment. (Previous h/o myocardial 
infarction)  
3. Severe co morbid conditions like pneumonia, alcoholic liver disease and hypotension  
4. Patients on β blocker and thiazide diuretics for their hypertension during the study 
period 
5. Patients with history of intake of the anti cholesterolemic agents 
6. History of cigarette smoking  
7. Any evidence of connective tissue disorder, particularly SLE    
8. Bilateral renal artery stenosis, as a cause for the CKD  
9. Patients with the features of hypothyroidism and obstructive liver disease  
 
 
 
Materials and methods: 
 
                  This study was conducted in THANJAVUR MEDICAL COLLEGE 
NEPHROLOGY department. By applying the inclusion and exclusion criteria we selected 41 
patients for our study, among them 29 were male and 12 were female. 
            After proper history taking and the clinical examination, we did the basic investigations 
like, TC, DC, ESR, HB%, RBC count, and platelet count.  
             Estimating the blood sugar, urea, creatinine and serum electrolytes assessed the renal 
functions. We estimated the size of the kidneys, with ultrasound scan abdomen. (We had taken 
the longitudinal size of <9 cms and the cross sectional size of <4 cms as a cutoff value). 
 
            Screening for the ischemic heart disease were done with the help of electro cardiogram 
and the patients were excluded, who were all taking the anti ischemic therapy, because this 
treatment alters the serum lipid levels.i.e:  
           Beta blockers – raises the serum LDL level with out altering the HDL level  
           Thiazides diuretics raise the triglyceride level and reduce the HDL level. 
                
            We took the blood sample for lipid profile analysis before starting the peritoneal 
dialysis. (Pre Dialysis lipid profile sample)  
 
           We did the peritoneal Dialysis for the patients, who were all in the uraemic symptoms. 
Associated features present in these patients were 
     1. Hyperkalemia 
     2. Metabolic acidosis 
     3. Extra cellular fluid volume expansion  
 
  Procedure during dialysis: 
 
         Materials we were used for the dialysis, 
1. Peritoneal dialysis catheter – straight Tenckhoff catheter. 
2. Peritoneal Dialysis transfusion set. 
3. Dialysate fluid. 
4. Material for sterilizing the surface. 
5. Suture material for fixing the catheter.  
 
   Composition of the Dialysate fluid, what we used for this study: 
        Each 100 ml contains 
1.  Magnesium chloride – 0.0152 gm 
2. Calcium carbonate     - 0.0220 gm 
3. Sodium acetate      - 0.4760 gm 
4. Dextrose an hydrase – 1.7 gm 
5. Sodium meta bisulphate -0.0150 gm 
6. Water for injection. 
 
Osmolality is approximately 355mosmol /l 
Solution contains approximate mmol/l of 
1. Sodium 130 
2. Calcium 1.5 
3. Magnesium 0.75 
4. Chloride 100 
5. Bicarbonate (as acetate) 35 
 
           With this above material we properly sterilize the abdomen with povidone iodine and 
spirit, we made a small incision in the Abdomen in the sub umbilical region, we introduced the 
catheter through the sub-umbilical incision and positioned the catheter tube in the either one of 
the flanks. Drain was checked and the stay sutures applied for the catheter. Broad-spectrum 
antibiotics prescribed for the patient. 
          Duration of the dialysis:  We subjected the patient to dialysis for continuous 48 hrs a 
period.  
                 At the end of the dialysis procedure we sent the blood sample for the lipid profile 
analysis (post dialysis sample). 
 
     Additional investigations needed in this study: 
1. 24hrs urinary protein estimation 
2.  creatinine clearance. 
 
    Procedure used to measure the serum creatinine and creatinine clearance – AUTO 
ANALYSER TECHNIQUE – using   jaffe reaction. 
 
 
 
 
 
 
 
 
Analyzing the Sensitivity and specificity of the investigations, what we used in 
this study.  
We used plasma urea, serum creatinine, creatinine clearence and ultrasound scan 
abdomen were the necessary investigations to satisfy the criteria for the chronic kidney 
disease. 
 
1. Plasma urea: 
Urea is one of the first indicators for the used to measure the renal function. Plasma urea 
is a poor measure of the GFR. Urea production is variable largely depends on the protein 
intake. Thus the kidneys excrete most of the urea 25,26. It can be readily reabsorbed in the 
tubules. In conditions like low antidiuretic hormone levels, the medullary collecting tubules are 
impermeable to the urea. In conditions with low effective intravascular volume having high 
ADH level, the urea reabsorption can be substantial. Some substances are interfering with the 
urea estimation ie  Falsely high urea level-                    
aminosaliocylic acid, bilirubin, lipemia, dextran, uric       acid, free haemoglobin   
 Falsely low urea level –  
         Ascorbic acid, levodopa, and lipids. 
 
 
2.Serum creatinine: 
          Serum creatinine is the most widely used indirect measure of GFR. Serum creatinine is 
very insensitive to even substantial decline in GFR34. GFR measured by most accurate 
techniques may be reduced by up to 50% before serum creatinine becomes elevated. It is 
insensitive because,       
 1. Serum creatnine with muscle mass; 
              Serum creatinine value in young in normal range indicates the normal GFR. 
The same level in the elder individual could indicate a twofold reduction GFR.32        
         2. Proportional tubular secretion of serum creatinine increases with the decreasing GFR. 
 3. With declining kidney function extra renal degradation of the creatinine 
increases.35,36,37 
 
Numbers of methods used to measure s.creatinine.     
1. Original Folin – wu 40method- using Jaffe reaction. 
2. Method of hare – using Lloyd reagent. 
3. The direct Alkaline Pictrate method. 
4. Auto analyzer using Jaffe reaction. 
 
       A number of normal plasma constituents can interfere with creatinine measurement. They 
are glucose, fructose, pyruvate, acetoacetate, uric acid, ascorbic acid and plasma proteins. These 
normal constituents cause Jaffe’s colorimetric assay to yield high value. These interfering 
chromogens increase the creatinine value by about 20%. 
         One study has shown that, in normal individuals the contributions of the nonchromogens 
in serum creatinine is about 14%, and in CKD patient’s nonchromogen contribution in 
creatinine is about 5%. 
          Several modifications in Jaffe reaction have done to remove the interfering chromogens. 
Fuller earth and ion exchange resins used to remove the non-chromogens. 
         These methods are replaced by less costlier and more convenient auto analyzer technique 
using the Jaffe reaction. This technique perpetrates the creatinine from non-chromogens. Thus 
avoids the disadvantage of the standard method. 
     In our study we utilized the AUTO ANALYSER method 39 using the Jaffe reaction.  
3. Creatinine clearence: 
         The renal clearence of the creatinine is, the urine creatinine excretion divided by the area 
under the plasma creatinine concentration – time curve for the period in which the urine was 
sampled. 
       
    The creatinine clearance rate more closely resembles the GFR. 28    
The reliability is greatly diminished by  
1. Variability of the tubular secretion of creatinine 33 
2. Inability of the most patients to collect the urine properly for 24 hrs 
3. Prolonged storage of the urine that falsely raise the urine creatinine by 20% 
           Creatinine clearance calculated by the Jaffe reaction tends to be falsely low (under 
estimates GFR).  Plasma constituents falsely raise the serum creatinine level, whereas urine 
creatinine level is largely unaffected. In a given population this error tends to cancel the error 
introduced by tubular creatinine secretion. The two errors are independent, and the occurrence 
of the opposing errors of the same magnitude in the same patient is largely a result of chance. 
              The creatinine clearance is measured by using serum creatinine level and other clinical 
parameters. 
     
Using the cockcroft gault formulae the estimated creartinine clearance is measured by 
this following formulae.42 
                                                                                                           (140-age)  
x   weight in kg 
                        ---------------------------------- X 0.85 if female 
                           Serum creatinine x 72  
 
4. Ultra sound scan abdomen:     
            This is the most sensitive method to diagnose the chronic kidney disease. In end stage 
renal disease (ESRD) we expect the kidney size to be reduced and Cortico Medullary 
differentiation couldn’t be differentiated. 
           The parameters used in ultra sonogram abdomen for the kidney disease are 
1. Length – 9 to 12 cms 
2. Width   - 4 to 6 cms 
3. Thickness - <3.5 cms 
4. Cortico Medullary Segment differentiation 
                  
In chronic kidney disease the size of the kidney is much reduced. The patients is in the need of 
dialysis usually have the length of the kidney is < 9 cms. 
In our study most of the cases have the kidney size is < 8 cms in length 
 
Background of the study:  
              Peritoneal dialysis is an emergency and life saving procedure for the ESRD patients.   
             In THANJAVUR MEDICAL COLLEGE, we are doing this procedure in 
NEPHROLOGY unit for the ARF & CRF patients, who were all admitted in the state of 
pulmonary edema. 
            Because of the poverty in our area, most of the patients cannot afford for the 
sophisticated procedure like CAPD, CPPD, IPD and Haemodialysis.  We are in the need to use 
the peritoneal dialysis procedure extensively. 
            References from the journals and Internet, shows lipid profile changes and 
atherosclerosis events are common in the pts undergoing dialysis.  So we conducted this study 
on the background of these references.  
             It spite of this procedure being extensively used in this instititution no similar study was 
conducted previously to evaluate this risk factor, so we conducted this study to evaluate this risk 
factor and compare it with prevailing trends. 
 
 
 
 
Literature review: 
 
Definition of the chronic kidney disease:        
      A. Kidney damage for 3 months or longer, as defined by structural or functional 
abnormalities of the kidney, with or without decreased glomerular filtration rate manifest by 
either      
         1. Pathological abnormalities, 
         2. Markers of kidney damage, including abnormalities in the composition of the blood or 
urine or abnormalities in the imaging studies.  
       B. Glomerular filtration rate less than 60ml per minute per 1.73 m2 for 3 months or longer 
with or with out kidney damage.2 
 
 
 
 
 
 
 
 
 
 
 
Staging for the CKD  
National kidney foundation staging for the chronic kidney disease:   
Stage Description  GFR, ml per 
m2 
Prevalence n 
(%) 
Action 
    - At increased risk  >60ml(CKD 
risk factors) 
      - CKD risk 
reduction 
  1      Kidney damage 
with normal or 
increased GFR 
> 90 5,900,000(3.3) Diagnosis 
and 
treatment: 
treatment of 
the co morbid 
condition. 
Slowing the 
progression 
 2 Kidney damage 
with slightly 
decreased GFR 
60 -89 5.300,000(3) Estimating 
the 
progression 
 3 Moderately 
decreased GFR 
30- 59 7,600,000(4.3) Evaluating 
and treating 
the 
complication 
 4 Severely decreased 
GFR 
 15 – 29  400,000(0.2) Preparation 
for kidney 
replacement 
therapy 
 5 Kidney failure   < 15 300,000 Kidney 
replacement 
 
 
 
 
 
CAUSES OF THE ESRD: 
Diabetes mellitus and hypertension are the major causes of the ESRD undergoing the 
Dialysis.45 
Glomerulornephritis is the third most common cause of the ESRD undergoing Dialysis. 
Other causes for the ESRD: 
1. Tubulo interstitial nephritis 
2. Infection and reflux nephropathy 
3. Polycystic kidney diseases. 
4. Haemolytic uraemic syndrome/ thrombotic thrombocytopenic purpura. 
5. Vasculitis (wegeners granulomatosis, polyarteritis nodosa) 
 
 Risk factors for the progression of the ESRD: 51 
1. Ethnicity 
2. Gender – male > female 
3. Smoking 
4. Heavy consumption of the non- narcotic analgesics. 
 
 
 
Treatment modalities for the ESRD: 44 
    Haemodialysis 
    Peritoneal dialysis 
    Renal transplantation 
Types of peritoneal dialysis; 
1. CAPD- continuous ambulatory peritoneal dialysis 
2.  APD- automated peritoneal dialysis 
3. IPD – intermittent peritoneal dialysis 
 
Types of haemodialysis : 
1. In center haemodialysis 
2. Home HD  
 
 
 
 
 
 
 
 
PRICIPLES OF PERITONEAL DIALYSIS: 
Component of the peritoneal dialysis system 
1. PD catheter 
2. PD solutions 
3. Peritoneal membrane and its vascular supply. 
I. PD catheter: 
       Palmer and coworkers first introduced the catheter in 1963 and Tenckoff and Schechter 
modify it in 1968. 
 
Catheter design: 
   1. Acute use catheter - is straight, relatively rigid conduits about 3 mm in diameter and 25 to 
30 mm in length.  This catheter is associated with increased risk of infection and malfunction, 
and this should not be in place for more than 3 days. In ARF pts usually require treatment for 
longer than 3 days. 
2. Chronic use catheter: 
                The standard chronic use catheter is constructed of soft materials like silicone rubber 
or polyurethane. Silicon catheter is commonly used, and it is biocompatible. Polyurethane 
catheter has small wall, but cracking of the catheter has been reported. 
 
 
 3. Catheter design: 
         Straight Tenckhoff catheter were associated with high rate of external cuff excursion and 
migration, so swan neck catheter 46,47 were developed. It has bend and arc to prevent migration 
and cuff excursion. The downwardly placed exit and placement of the subcutaneous cuffs are 
designed to decrease the likelihood of the cuff excursion and exit.48 
 4. Catheter implantation technique: 50 
   General standards of the chronic catheter placement 
1. The deep cuff should be in the anterior abdominal wall 
2.  The subcutaneous cuff should be near the skin surface and not less than 2 cm from the 
exit site to allow for drainage and provide a firm anchorage.  
3. The catheter exit should be placed laterally 
4. The catheter exit should be directed downwards and laterally.57 
5. The intra abdominal portion of the catheter should be placed between the visceral and 
parietal peritoneum.  
The methods used for catheter placement49 are surgical insertion, peritoneoscopic 
insertion, blind placement, moncrief- popvinch technique. 
 
II. Dialysis solutions: 
Standard dialysis fluid contains electrolytes, buffers, and osmotic agents. 
   1. Electrolytes:  
       Sodium: sodium has been added to dialysate fluid in varying range from 120 to140 mEq/l. 
sodium doesn’t cross the peritoneal membrane as readily as the water. The concentrate of 
sodium in the ultra filtrate is lower than the serum; it is around 70 mEq/l 52,53,54. . The transient 
decrease in the dialysate sodium occurs during the dwelling period due to the aquaporin 
mediated trans cellular water movement that is sodium free, a process called sodium seiving.  
After multiple exchanges systemic hypernatraemia has been described. To avoid this problem 
most commercially available dialysis fluids have a sodium concentration of 132mEq/l. 
 
Calcium:   Control of calcium and phosphate balance in ESRD is important to prevent the long-
term complications of renal osteodystrophy55,56 . Phosphorous is poorly removed from PD. 
Because of the complication of the aluminum, used as a phosphate binder, now we are using the 
calcium in high concentration (3.5mEq/l). This calcium concentration would also correct the 
hypocalcaemia in an ESRD. This high concentration of calcium would cause hypercalcemia and 
metastatic calcification. So in modern ideal dialysis fluid contain the calcium concentration of 
around 2.5mEq/l. 58,59    
        Clinical trials show this calcium concentration would improve the biochemical properties. 
(s. Calcium, phosphorous, alkaline phosphate, and parathyroid hormone level)  
       
2. Buffers:  
Current standard fluid contain lactate and bi-carbonate buffers. 
Lactate buffer system: Lactate replaces the acetate60, which used in the early period as a buffer 
because of the ultra filtration failure. This filtration failure was due to the development of the 
sclerosing peritonitis61.  Acetate buffer would take longer time to reach physiologic PH during 
the dwell period than lactate will cause increased pain on inflow. 
         Lactate buffer are available in fluid as D-form and L-form. The important complication of 
these buffers is they are absorbed and supraphysiologic concentration is associated with 
encephalopathy.  
Bicarbonate buffer system: important disadvantage of this systems are, precipitation of the 
calcium, magnesium and caramelization of glucose at physiologic PH. To avoid this problems 
addition of glycyl glycine has been done.62 
 
Now the standard buffer system in dialysis fluid is lactate / bicarbonate mixture. 
4.Osmotic agents: 
Glucose: it is safe, effective, readily metabolized and inexpensive. Glucose is not an ideal 
osmotic agent because, 
i. Rapid absorption 
ii. Potential for metabolic complications, hyperglycemia, hyperinsulinemia, 
hyperlipidemia, obesity.23,24 
iii. Necessity for an acidic dialysis PH to prevent caramelization. 
iv. Potential non-enzymatic glycosylation of peritoneal tissue during periods of 
mesothelial cell loss. 
 
 Amino acids: protein malnutrition is a significant risk for morbidity and mortality in dialysis 
patients. Because of the dialysis loss of protein and amino acids into the PD, amino acids 
containing fluid would be the caloric source.  Other benefits of amino acid absorption is, that to 
cause intra peritoneal vasodilatation, that increasing the surface area for the dialysis63.  The 
1.1% amino acids effectively replace the protein loss through the dialysis fluid. 
             The main disadvantage of the amino acids is the development of the metabolic 
complications and increased levels of serum urea nitrogen level  
Polypeptides and oligopeptides :  
  Main advantages of polymers are  
1. Prolonged ultra filtration, because of higher average molecular weight 
2. Presence of ionized branched chain that provide higher osmotic pressure on a 
molar basis, 
3. Potential for providing protein based calories. 
4. It lowers serum cholesterol level and reduces serum insulin level and insulin 
sensitivity. 
   Main disadvantage of polymers; Rash, Exfoliative reactions, Sterile peritonitis   
Advantage of poly glucose over glucose a comparison; 
1. Glucose induces trans capillary ultra filtration across both small inter endothelial and ultra 
small trans cellular pores; whereas poly glucose induce ultra filtration across inter 
endothelial pores. 
2. Glucose and poly glucose have markedly different trans capillary ultra filtration profiles. 
3. Ultra filtration with glucose is rapid and occurs in early period and decreases with time; 
whereas poly glucose ultrafiltration increases linearly with time. 
4. Glucose is absorbed so that crystalloid induced osmotic gradient is no longer present, ultra 
filtration ceases and lymphatic absorption of fluid predominates; whereas poly glucose is 
slowly absorbed through lymphatics.64   
 
 
An ideal peritoneal dialysis solution: 65 
      1. Good solute clearance and ultra filtration capacity   
3. Necessary solutes supplied and uremic toxins removed. 
4. Nutrition supplied or does not promote catabolism.  
5. Isosmolar solution, normal pH, bicarbonate as buffer 
6. Minimal absorption of osmotic agent 
7. Anti bacterial and anti fungal properties. 
8. Membrane biocompatible/ doesn’t promote chronic inflammation. 
 
  
 
III. Peritoneal membrane: 
Anatomy; 
       Membrane is the primary interface between the blood and the Dialysate fluid. It contains 
two principal parts 
1. Parietal peritoneum – 10% of the total  
2. Visceral peritoneum  - 90% of the total  
The Total surface are of the Peritoneal membrane is 1 to2 m 2 . Children have disproportionately 
larger peritoneal surface than adults. The Peritoneal surface is continuous and closed in males. 
In females it is continuous with the mucous membrane of the fallopian tube. Intra abdominal 
opening is normally collapsed; there is no free communication. The Peritoneal cavity contains 
about 100ml or less of fluid normally. It has the capacity to accommodate 2 liters or more. 
Mesothelium: 
      This is a continuous monolayer of flattened cells, which about 0.5 mm thick. The free 
surface of the Mesothelium is covered by microvillus that increases the surface area. It contains 
tight junctions, which have an anchoring between cells of one another and basement membrane 
66,67. It contains gap junctions, which mediate the passage of chemical or electrical signals.  
Mesothelial cells are ultra structurally similar to Type II Pneumocytes 68. They contain the 
lamellar bodies identical to those Pneumocytes. These cells secrete surfactant like lubricant 
material.   
          Sub Diaphragmatic stoma, allows the direct contact between the peritoneal fluid and 
lymphatic, through which the peritoneal fluid got absorbed.  
Basement membrane: 
    It is a homogenous membrane contains openings in the diaphragmatic surface, made up of 
Type IV collagen proteoglycans and glycoproteins.  It is a selective barrier by preventing the 
fibroblast from contacting Mesothelial cells. 
Interstitium:  
     It is a primary support for the Peritoneum. It is made up of the Mucopolyscharide matrix. 
The Interstitium contains the aqueous and lipophilic phases for the transport of the substances. 
Blood vessels: 
      The celiac and mesenteric arteries supply visceral peritoneal membrane with venous 
drainage via portal veins.  
      Parietal peritoneum is supplied by circumflex, iliac, lumbar, inter coastal and epigastric 
arteries with drainage into the systemic veins. 
        The capillary wall contains at least two different pores, larger pores situated in the Venular 
end and the small pores situated in the capillary end. 
Peritoneal lymphatics: 
       Intersitial fluids and solutes are removed by the lymphatic vesssels. They also function to 
maintain 50 to100ml of fluid in the Peritoneum. The fluid absorption mainly occurs through the 
stomas in the sub-diaphragmatic peritoneum. 
 
PERITONEUM AS A DIALYSIS SYSTEM: 
There are potential resistance sites present in the peritoneal membrane to transport the fluid and 
solutes. They are 
1. Fluid films within the capillary lumen 
2. The endothelial layer 
3. The capillary basement membrane 
4. The Interstitium 
5. The Mesothelial layer 
6. Fluid film in the peritoneal cavity. 
 
The solute transport occurs by both diffusive 70 and convective forces. The mass transport 
barrier appears to offer very little resistant to diffusion process, and offer significant resistance 
to the convection process. Resistance to flow of solute is greater than resistance to flow of 
water.  
 
Intracapillary fluid films - exert little resistance for the low- molecular-weight solutes 69. 
 
Capillary endothelium – It is a selective barrier to solute transport, low resistance barrier to low 
molecular weight solutes, and offer significant resistance to molecular, which increases further.  
The transport across the capillary endothelium is defined as a three-pole model. 
1. Water channels – analogous to aquaporins, these channels are sensitive to crystalloid- 
driven osmosis. 
2. Small pores – this inter endothelial clefts with a radius of 4 to 6 nm – 90 to 93% of the total 
pole area. These poles restrict the passage of the proteins, but allow the urea, creatinine and 
water. 
3. Large pores – which have radii larger than 20 nm and are probably located in the venular 
side of the pore area 71. 
  Diffusion is postulated to occur through large pores located at the Venular end of the 
capillaries. 
  Convection occurs through the small poles at the arterial end of the capillaries. 
Capillary basement membrane: 
  This membrane produces little effect on the diffusion of low molecular – weight solutes. The 
anionic sites predominantly composed of Heparin sulphate and Chondroitin sulphate, inhibit the 
transport of the charged solutes. 
 
Interstitium:  
    The longest distance the solute must traverse. This is the major site of resistance for urea and 
low molecular weight solute.  The gelatinous mucopolyscharide matrix interspersed with water 
rich, colloid poor membrane offers the resistance. The fixed ionic charges on the collagen and 
mucopolysacharides may influence the transport of charged solutes. 
 
Mesothelium:   
     This is more permeable than endothelium; because of the larger inter cellular gaps. Visceral 
mesothelium is more permeable. Surface-active phospholipids adsorbed on to the mesothelial 
lining and maintaining the integrity of the semi-permeable properties of the membrane. 
 
 
 
Complication of the peritoneal dialysis:  
1. Cardiovascular complications 
2. Infectious complications  
3. Non infectious complications 
1. Cardiovascular complications: 
            Mortality and morbidity from cardiovascular disease are greatly increased in patients 
on maintenance dialysis therapy. Cardiovascular mortality continues to account for more 
than 50% of death in haemodialysis patients. The cardiac mortality can arise from arrythmia, 
cardiomyopathy, and ischemic heart disease. 
          The first report of accelerated atherosclerosis in dialysis patients originated in the 
1970s from scribe and colleagues based on their experience. Their report with ACSVD 
prevalence varies from 24% in non-diabetic patients on dialysis to as high as 85% of 
diabetics on dialysis. Their post morterm examination report of coronary atherosclerotic 
disease in dialysis and control confirm more calcified plague in patients with ESRD on 
dialysis.  Increased medial thickness is characteristic of coronary plagues in dialysis. 
Hypertension: 
      This is very common and occurs in 50 to 90 % of the PD patients. Hypertension in PD 
patients is due to fluid retention as a result of the impaired ultra filtration 72. This increases the 
risk of the LVH and cardio vascular morbidity and mortality. Prescribing the loop diuretics, 
preservation of the residual renal function, reduction of dietary salt intake and limitation of fluid 
intake and prevention and treatment of the ultra filtration failure can prevent this complication. 
 
Hyperlipidaemia: 
           PD is associated with increased glucose load because of the constant absorption from the 
peritoneal cavity 23,24. So the patients have constant susceptibility to the development of the 
hyperinsulinemic state. This hyper insulinemic state increases the synthesis of triglycerides in 
the liver 8. The dialysis procedure results in loss of 5 to 15g of protein per day, preferably small 
molecular weight proteins, so there is a loss of HDL lipoprotein 73 is the rule. 
         Initiation of the PD significantly increases the synthesis of serum cholesterol, serum 
triglycerides and total cholesterol 3,4,6,7 levels. The total cholesterol shows the predominant 
increased in the LDL level. The strongest predictors of the lipid profiles are weight gain, higher 
plasma glucose level and preexisting cardiovascular co morbidity. The serum lipid protein 
analysis shows elevated levels of Lp (a) 5 and apo proteins, including apo-A and apoB 
containing lipoproteins, apoCIII, apoB, apoC levels.  The increased Lp (a) level is due to 
increased synthesis, not due to decreased clearance. Lp(a), an atheorogenic lipoprotein consists 
of low density lipoprotein cholesterol particle that is covalently bonded to apolipoprotein (a), a 
glycoprotein  with genetic polymorphism.  
             An inception cohort study of incident dialysis patients followed prospectively 
demonstrated that small apo lipoprotein (a) size predicts mortality, even with multiple 
adjustments for demography, comorbidity, cause of renal failure and congestive cardiac failure. 
              The dietary modification shows minimal reduction in the serum lipid levels. The use of 
1.1% amino acid dialysate exchange per day did not report any improvement.  The use of 
polyglucose solutions has been associated with a decrease in lipid levels 22. 
            Hypercholesterolaemia in PD patients has been successfully treated with atorvastatin 
and gemfibrosil. Hyper triglyceridemia has been treated with atorvostatin, fibric acid derivatives 
and fish oil supplementation. 
 
C- reactive protein: 
      PD patients have serologic evidence of an enhanced inflammatory response 10,11. Factors 
that cause the enhanced inflammatory response include the decreased renal clearance, the 
biocompatible dialysate solutions and co morbid medical conditions. The acute phase reactants 
such as CRP, Lp(a), Fibrinogen and proinflammatory cytokines(IL 6) are elevated, they have  
direct atherogenic  properties 14,15,16.  Plasma levels of C-reactive protein as a marker of acute 
inflammatory reaction have been demonstrated in prospective cross section studies and in 
cohort studies to be a powerful predictor of cardio vascular disease and all cause mortality in 
dialysis patients. Approximately 30 to 60 % of PD patients have elevated CRP levels. 
         Hypoalbuminemia is also associated with elevated CRP level.  It is a negative acute phase 
reactant. The strong association between atherosclerosis, elevated CRP, and hypoalbuminemia 
has lead to the term Malnutrition Inflammation Atherosclerosis syndrome (MIA syndrome) to 
describe the micro inflammatory process. 
       The presence of the pro inflammatory cytokines IL-6 has similarly been associated with the 
presence and subsequent progress of underlying atherosclerosis in dialysis patients.  
 
  Homocysteine:  
           Most PD and HD patients have elevated homocysteine levels; patients with low folate or 
vitamin b12 levels are at increased risk of having elevated homocysteine  16,17,18,19 levels. PD 
removes Homocysteine; the removal is not high enough to allow for the correction of the 
homocysteniemia. The amino acid containing PD solutions, which have methionine, cause an 
increase in homocysteine level.  Elevated homocyteine in long-term dialysis patients predicts 
the ASCVD. 
 
Oxidative stress: 
           Oxidative stress is also highly prevalent in haemodilysis patients and may contribute to 
an acceleration of atheroscelrosis.  Oxidation of LDL, particularly in the subendolthelial space, 
leads to uptake of oxidized LDL by monocyte- macrophage, and conversion in foam cells, the 
earliest stage in atherosclerotic process. Oxidative stress may occur in dialysis patients directly 
as a result of impaired renal clearance of oxidants and by increased production by activated 
macrophages. This increased oxidative stress contributes to cardio vascular disease, evaluated in 
SPACE study. (Secondary   prevention with antioxidants of cardio vascular disease in end stage 
renal disease) 
 Other cardio vascular risk factors: 
• Nocturnal hypoxemia may also be an important predictor. 
• Corrected QT dispersion (difference between the shortest and longest QT intervals) is a 
meaure of regional heterogenicity in myocardial repolarization. 
• Asymmetrical di-methyl arginine, an endogenous nitric oxide inhibitor that accumulates 
in uraemia, shows significant correlation with atherosclerosis. 
 
 
Angina in dialysis patients: 
    The presence of severe coronary artery disease without symptomatology is commom in HD 
patients. 
      75% of diabetic patients with angiographically significant CAD had no symptoms. Similarly 
findings have also been identified in non-diabetic HD patients. The lack of anginal symptoms in 
non-diabetics may be explained by uraemic autonomic neuropathy or by low level of physical 
activity in long-term dialysis patients. 
         To evaluate the asymptomatic CAD, Ambulatory electro cardiographic recordings have 
not been well studied in HD patients. Exercise electrocardiography is affected by abnormal 
resting electrocardigram and by markedly reduced exercise tolerance. There are conflicting 
reports about usefulness of Stress Echocardiography and Exercise stress test.  Relatively high 
sensitivity and specificity has been reported for Dipyridamol exercise Thallium Imaging and 
Dobutamine stress Echocardiography.     
 II. Non- infectious complications: 
    Mechanical complications; 
        In flow pain 
        Outflow failure 
        Catheter damage 
   Intra abdominal pressure: 
          Hernias 
          Dialysate fluid leak    
          Hydrothorax  
         Alterations in the respiratory function 
          Back pain 
 
 
 
 
 
 
 
 
 
OBSERVATION NO 1  
General character of the study group; 
                41 patients were included in this study, among them 29 were male and 12 were 
female. All of them were known hypertensive patients. The duration of the hypertension varies 
from 1½ yrs to 15 yrs.  
               When analyzing the body weight of the study population, their body weight ranges 
from 38 kgs to 70 kgs. Mean body weight of the male patients was 63.13 kgs. Mean body 
weight of the female patients was 55.1 kgs 
All the patients involved in our study were non-diabetics. Their mean blood sugar 
levels were 101 mgs%. 
              All the 41 patients satisfied the criteria for the peritoneal dialysis. Their mean urea 
levels were 148.5 mgs% and mean creatinine levels were 11.09 mgs%. 
                 
Male(29)
Female(12)
Male(29) Female(12)
 
 
 
OBSERVATION 2:  
Analysis of age distribution in the study population;  
 
Age group Male patients Female patients Total no of 
patients 
0 -19 0 0 0 
20-39 2 0 2 
40-49 6 5 11 
50-59 13 5 18 
60-69 6 2 8 
70-79 2 0 2 
Total  29 12 41 
 
 
               The age group of our study population falls between 38 –70 years of age. Most of the 
study population falls between the ages of 50 –59 yrs in our study. The mean age of the study 
population is 52.5 yrs.  
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OBSERVATION 3 
ANALYSIS OF THE PATIENTS WITH HYPERTENSIVE 
RETINOPATHY: 
Total no. of patients with retinopathy –24. 
Fundus changes No of patients 
Normal  17 
Grade I 5 
Grade II 13 
Grade III 1 
Pappiloedema  5 
 
Opthalmological examination revealed the fundoscopic changes in our study group. 59% of 
male patients (17 males) and   58% female patients (7 females) have hypertensive retinopathic 
changes. Among the patients, 17 have normal fundus, 13 have grade II retinopathy changes, 5 
have pappilloedema, 5 have grade I changes and 1 patient have grade III changes 
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OBSERVATION 4 
 
ECG features No of patients 
CAD 21 
Hyperkalemia 13 
Normal  7 
 
When analyzing the electrocardiographic finding of the study group, 21patients (51.2%) had the 
features of coronary artery heart disease, 13 patients (31.7%) had features of hyperkalemia and 
7 patients (17%) had normal findings.  The CAHD patients were not on anti ischemic therapy 
previously 
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OBSERVATION 5 
Analysis of the creatinine clearance of the study population 
 Male   Female  
Creatinine clearance  
 <10 ml/min 
26 8 
Creatinine clearance 
10-30ml/min 
3 4 
 
Among the 41 patients in our study, most of the patients have their creatinine 
clearance of < 10 ml/min. 90% of the males (26 patients) and 67% of females (7patients) had 
their creatinine clearance < 10 ml/min.  Rest of the patients had their creatinine clearance falls 
between 10 – 30 ml/min. their mean creatinine clearance was 7.4 ml/min. 
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RESULT 1 
 Patients with post dialysis elevation of ATHEROGENIC LIPIDS in the serum (expressed in 
no.) 
s.no   Male  Female 
1. Increase in TGL 19   7   
2. Increase in LDL  18   8   
3. Reduction in HDL 9   9  
 
After 48 hrs of continuous peritoneal dialysis 19 out of 29 males (65%) and 7 out of 12 females 
(58%) had the rise in Triglyceride levels, 18 out of 29 males (62%) and 8 out of 12 females 
(67.5%) had rise in the low density lipoprotein levels and finally 9 out of 29 males (31%) and 9 
out of 12 females (78%) females had a reduction in the High density lipoprotein levels 
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RESULT 2 
Analysis of the number of patients with elevated TGL level in the serum 
 Male Female  
Predialysis  13 6 
Post dialysis 22 7 
 
       In the study population, 13 male patients and 6 female patients has rise in their serum TGL 
level above 150 mgs/dl. Most of them show borderline elevation around 150% mgs to 160 
mgs%.  In the post dialysis sample, 22 males and 7 females has significant rise in the serum 
TGL level. Most of the serum TGL levels exceeds 180 mgs%. This rise is very significant. 
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RESULT 3 
Analysis of the patients with elevated LDL level in the study group. 
 Male  Female  
Pre dialysis 20 11 
Post dialysis 22 12 
 
When observing the pre dialysis LDL level, 20 out of 29 males and 11 out of 12 females had 
elevated LDL in their serum. In post dialysis sample 22 males and 12 females has elevated LDL 
level in their serum.  
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RESULT 4 
Analysis of the patients with reduced HDL level in the study population  
 Male  Female  
Pre dialysis  10 7 
Post dialysis 9 11 
 
           By observing this table the number of patients with HDL fall is more in the females than 
males.  
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RESULT 5 
Analysis of the mean TGL in the study population  
Pre dialysis mean TGL 
      Male- 4418/29 = 152.34 mg/dl 
    Female –1873/12 = 156.08 mg/dl 
Post dialysis means TGL 
      Male – 5157/29 =177.82 mg/dl 
    Female - 2115/12 =176.25 mg/dl  
 Male  Female 
Pre dialysis 152.34  156.08  
Post dialysis 177.82  176.25 
P value <0.05 >0.05 
 
  The mean pre dialysis TGL level in males and females are 152.34 mgs /dl and 
156.08 mgs /dl respectively. This level rose to 177.82 mgs /dl in males and 176.25 mgs /dl 
females after the dialysis. P value shows the 5% level significant difference between two means 
in males, but insignificant difference of 5% level between two means in case of females. 
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RESULT 6 
Analysis of the mean LDL level in the study group: 
Pre dialysis mean LDL 
      Male –3937/29 =136.31 mg/dl 
   Female –1712/12 =142.67 mg/dl 
Post dialysis mean LDL 
     Male –4340/29 =149.62 mg/dl 
  Female –2017 /12 =168.16 mg/dl 
 Male  Female  
Pre dialysis 136.31 142.67 
Post dialysis 149.62 168.16 
P value >0.05 >0.05 
 
         P value shows statistically insignificant difference of 5% level between the two values in 
males and females. 
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RESULT 7 
Analysis of the mean HDL level in the study 
Pre dialysis mean HDL 
        Male – 1136/29 = 44.31 mg/dl 
     Female –570/12  = 47.5 mg/dl 
Post dialysis mean HDL 
       Male – 1233/29 = 43.21 mg/dl 
    Female – 578/12 =43.17 mg/dl 
 Male  Female  
Pre dialysis 44.31 47.5 
Post dialysis 43.21 43.17 
P value >0.05 >0.05 
 
P value shows statistically insignificant 5% level between the two means in case of males and 
females. 
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Discussion: 
According to the ATP III guidelines: 
 Risk factors for the atherosclerosis are: 
1. Central obesity (waist circumference)  - >102 cms (males), >88cms (females)  
2. Hypertriglyceridemia ->150 mg/dl 
3. Low HDL - <40 mg/dl (males),  <50 mg/dl (females)  
4. Hypertension >135/85 mmHg 
5. Fasting blood sugar 110 –125 mgs%. 
          The atherogenic lipoproteins in the blood in patients undergoing peritoneal dialysis are 
elevated LDL, elevated Triglycerides, elevated Lp (a) level and low HDL. According to the 
ATP III 2001 guidelines the dialysis is an atherogenic event. 
            The apoproteins present predominantly in the LDL and TGL are apoB 100.  The 
apoprotein present predominantly in the HDL are apoA-I, which is protective to the atherogenic 
event.   
            The apoB48, present predominantly in the chylomicrons are not much atherogenic. 
         
       LDL is the cholesterol contains much rise in the apoB100 level, which is atherogenic. 
When this LDL is associated with the high TGL level the incidence of the atherogenisis is 
significantly elevated. Multiple lipid abnormalities are more atherogenic. 
     Low levels of the HDL are an indirect evidence of the elevated apoB100 level. 
        In the studies we had taken for the references most of them dialysis were done for 
prolonged period. The study conducted in Sweden, sahlgreska university hospital shows 12; their 
study period was 6 to 48 months. Their mean study period was 15.3 months. They had utilized 
the intermittent peritoneal dialysis procedure. They had monitored the bi-weekly creatinine 
clearance and glucose level in the study population. They had done the peritoneal dialysis 
procedure for the non-diabetic patients. In their study, they had significant rise in total 
cholesterol (7.1 mmol/ l), VLDL –cholesterol (1.0mmol/l), LDL cholesterol (4.7 mmol/l) and 
triglyceride level (2.5mmol/l).  They had statistically analyzed their results showed significant 
difference present between the analyses samples. They had analyzed in 95% and 99% 
confidence levels. 
            We have taken the ATP III guidelines and the above standard study as our reference we 
had undergone the study and analyzed the results. 
          We had taken the study population from the low socioeconomic status group. After 
satisfying the inclusion and exclusion criteria we had done the peritoneal dialysis for continuous 
48 hr period, whereas in the standard reference study, the study period varies from 6 months to 
48 months. In spite of these short 48 hrs period analyses, there is a rise in serum triglycerides 
(177.2mg/dl), serum LDL (168.08mg/dl) and serum HDL (43.1 mg/dl) were observed in our 
study. But when we statistically analyzed the results with paired t test in 95% confidence level, 
the rise in triglyceride in male patients is significant at 5% level. The rise in LDL and reduction 
in the HDL are statistically insignificant at 5% level.  
          Even though there is a rise in serum lipid levels in our study, the statistical analysis 
reveals the rise is insignificant at 5% level. When we compare to the reference studies, the 
duration of dialysis in our study is minimal (48 hrs). When we do the dialysis for longer period 
and by increasing the sample size, we can make our study statistically significant.    
 
 
 
 
 
 
 Conclusion: 
1. By doing the peritoneal dialysis in the ESRD, we should expect the elevation of the 
serum TGL, LDL & reduction HDL levels. 
2. By doing the peritoneal dialysis the Triglycerides in males and low-density lipoproteins 
in females are significantly elevated. 
3. The lipid elevation in peritoneal dialysis reaches the atherogenic level, according to the 
ATP III criteria; so peritoneal dialysis is also the one of the cardiovascular risk factor in 
ESRD patients. 
4. Anti Dyslipidemic agents like Stains and Fibrates might be prescribed in the patients 
undergoing long term peritoneal dialysis. 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
Picture 1: Shows the material for peritoneal dialysis; the catheter and the         infusion 
set. 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 2: The peritoneal dialysis on progress. Properly positioned catheter    and 
its haemostasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 3: The peritoneal dialysis on progress, in a 70 yrs old man with   
 chronic kidney disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 4: Ultrasonogram features contracted kidney. Size RK –8.6X3.6,                 LK –
8.7X3.4 
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S.NO AGE SEX IP.NO DM HT CAHD
1 40 male 856328 nil 3 yrs nil
2 40 male 855688 nil 7yrs yes
3 60 male 856383 nil 7 yrs IWMI
4 60 male 850928 nil 15yrs nil
5 65 male 846027 nil 5 yrs nil
6 55 male 840618 nil 2 yrs nil
7 40 male 849668 nil 3 yrs nil
8 70 male 850783 nil 7yrs nil
9 48 male 852122 nil 9 yrs nil
10 54 male 843424 nil 3 yrs nil
11 50 male 839308 nil 3 yrs nil
12 59 male 852960 nil 7yrs nil
13 70 male 839180 nil 12yrs nil
14 54 male 845217 nil 9yrs nil
15 65 male 845212 nil 6yrs nil
16 54 male 853337 nil 11yrs nil
17 65 male 848133 nil 11yrs nil
18 50 male 852816 nil 7yrs nil
19 45 male 842290 nil 1i/2 yrs nil
20 56 male 851666 nil 5yrs nil
21 38 male 843548 nil 3yrs nil
22 50 male 852671 nil 2yrs nil
23 55 male 847291 nil 11/2yrs yes
24 45 male 848289 nil 4yrs nil
25 60 male 859991 nil 7yrs yes
26 38 male 851626 nil 3yrs nil
27 55 male 841602 nil 4yrs nil
28 40 male 856755 nil 2yrs nil
29 50 male 847646 nil 2yrs yes
30 48 female 847885 nil 2yrs nil
31 45 female 844338 nil 5yrs nil
32 54 female 853816 nil 4yrs nil
33 53 female 853291 nil 7yrs nil
34 40 female 849499 nil 7yrs nil
35 63 female 853241 nil 11yrs nil
36 65 female 843417 nil 15yrs yes
37 45 female 860344 nil 6yrs yes
38 58 female 851141 nil 3yrs yes
39 40 female 843275 nil 8yrs yes
40 56 female 849537 nil 11yrs yes
41 54 female 844967 nil 6month nil
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WEIGHT BP FUNDUS SUGAR UREA CREATININE SODIUM S. K CR.CL
kgs mm/Hg mgs% mgs% mgs% mEq/l mEq/l ml/min
 
60 kgs 170/110 grade II 68 120 7.9 119 5.4 10.5
53 160/100 grade I 106 229 20.1 132 3.8 3.6
70 180/110 grade I 109 203 10.1 132 4.2 7.7
52 170/110 grade I 80 117 12.7 130 12.7 4.5
70 180/110 normal 118 186 10.8 132 5.3 7
63 160/110 papiloedema 81 78 5.2 135 5.6 11.4
69 160/110 normal 95 134 7.7 116 5.9 12.4
63 160/110 grade I 98 133 5.5 128 5.9 12
57 180/110 normal 111 140 11.2 134 5.2 6.5
51 180/110 grade II 106 160 9.9 120 6.8 6.1
52 190/110 grade  II 98 164 17.2 132 6.1 3
70 200/130 papiloedema 82 127 10.5 136 5.2 9
63 140/100 grade III 140 120 7.5 139 5.3 8.2
58 150/110 grade II 107 105 10.2 130 5.6 7.5
59 160/110 grade II 96 133 12.8 128 6.2 4.8
57 17/110 grade II 98 164 16.4 126 5.7 4.2
68 180/90 gradeII 113 134 13.3 127 3.4 5.3
68 200/120 normal 90 180 8.3 131 5.8 10.2
70 160/100 normal 82 127 10.5 136 5.2 9
70 160/100 normal 130 190 10.2 130 5.6 8.5
59 130/100 normal 96 140 10.9 128 5.6 7.6
70 180/90 normal 146 190 10.2 130 5.6 8.5
63 170/100 normal 82 165 10.8 117 6.4 5.5
59 140/100 normal 74 148 10.6 119 6.8 8.7
73 170/100 normal 88 235 12.5 128 6.8 6.5
58 180/100 normal 84 144 11.6 128 5.9 7
67 190/120 grade II 96 157 9.3 130 4.8 6
53 180/100 normal 96 240 18.2 133 5.1 4
48 210/120 papiloedema 130 145 13.5 126 7.3 5.8
38 140/100 grade II 130 105 10 123 5.4 5.9
55 160/100 normal 107 188 22.2 123 6.6 3
63 170/100 grade II 120 130 8.6 130 3.7 9
46 230/130 papiloedema 85 108 6.7 134 5.1 11.1
41 180/120 grade II 136 149 15.1 128 6.1 4
56 230/130 papiloedema 85 108 6.7 134 5.1 11.1
61 160/110 grade II 70 120 10 137 5.8 5.4
63 170/120 grade I 106 138 7.8 130 5.6 11
59 150/110 normal 98 94 5.6 132 5.6 10.1
65 170/100 normal 79 172 20.2 116 9.8 4
68 150/90 normal 126 173 5.1 133 5 15.5
46 160/110 normal 106 92 11.3 124 4.2 4.1
ETR CHART CONTAIN THE DATAS FOR THE DYSLIPIDEMIC CHANGES IN PATIENTS UNDERGOI
ECG
RK- cms LK- cms TGL LDL CHOLESTROL HDL TGL LDL CHOLESTROL
8.1x3.3 7.8x3.1 normal 136 136 190 53 138 103 179
7.2x3.9 7.3x3.3 HT 86 148 203 38 70 103 194
8.8x4.4 7.1x4.3 CAHD 176 93 180 52 161 94 176
7.3x3.8 7.4x3.2 IWI 146 87 149 33 119 92 145
8.1x 3.6 8.3x4.5 tall T 52 140 224 54 160 110 200
7.4x3.1 7.4x3.0 tall T 240 176 272 50 272 196 298
7.2x4.2 7.5x3.8 IWMI 237 159 243 36 309 131 238
7.3x4.5 7.9x3.6 LWI 240 176 272 50 272 196 298
9.5x4.1 8.3x4.2 normal 135 108 170 35 165 67 149
8.0x4.1 7.6x4.2 tall T 192 291 381 52 234 338 440
7.4x3.1 8.0x3.5 tall T 172 188 273 50 189 210 273
7.5x4.1 7.3x3.5 LVH 198 94 181 48 236 197 270
7.6x4.3 7.8x3.8 IWI 152 140 224 54 178 157 240
8.0x4.1 8.0x3.5 tall T 100 113 161 28 150 142 224
8.0X3.7 8.1X3.6 LVH 114 137 195 36 129 160 171
8.0x3.7 8.1x3.3 LVH 141 172 248 48 168 180 258
8.2x4.0 7.9x4.5 LWI 174 66 152 52 329 67 178
7.6x4.3 8.1x4.4 tall T 141 170 248 48 169 180 258
8.2x4.2 7.6x4.1 normal 198 94 181 48 236 197 270
8.1x3.8 7.2x4.0 LVH 100 113 161 28 150 142 224
8.0x4.5 7.9x4.1 tall T 156 141 220 48 156 152 228
7.1x4.1 7.5x3.6 IWMI 130 116 180 38 180 172 254
7.0x4.4 7.9x4.1 IWMI 190 172 260 50 180 178 266
6.9x4.1 7.8x3.6 tall T 184 99 135 49 224 133 111
8.0x3.1 8.0x3.0 tall T 111 178 248 48 109 190 258
7.1x4.1 7.7x3.8 normal 94 48 119 52 43 47 86
8.2x3.1 7.8x3.2 AWI 125 163 210 22 148 151 208
8.1x3.3 7.7x4.2 LVH 100 56 114 38 95 51 104
7.7x4.1 6.9x3.9 tallT,LVH 198 193 280 48 188 203 290
6.4x3.4 6.0x3.2 normal 143 130 197 53 180 149 207
8.4x3.6 8.2x3.6 tall T 159 129 212 52 139 102 167
7.8x4.1 7.6x3.3 sine wave 109 190 258 46 106 240 299
7.6x4.1 8.2x3.9 normal 112 137 200 40 95 131 193
7.6x3.6 7.8x4.1 tall T 199 150 228 38 290 120 228
8.4x3.1 8.3x4.2 LVH 160 118 193 43 187 153 230
7.1x3.1 7.7x4.2 LWI 117 107 286 56 102 273 325
7.2x4.3 5.8x4.4 LWI 141 170 248 48 169 180 258
7.7x4.1 8.1x3.6 AWI 158 148 218 38 226 144 233
7.2x3.6 7.7x3.9 wide QRS 216 221 320 56 350 209 328
8.6x3.1 7.2x4.1 IWI 239 100 196 48 161 115 185
7.6x4.6 7.4x4.8 normal 120 112 188 52 110 202 272
USG. ABD PRE DIALYSIS POST DIALYSIS
S. LIPID PROFILE - mgs%
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